Longeveron INC

Longeveron Inc. has reconstituted its Audit Committee following its annual meeting, ensuring compliance with Nasdaq listing rules.

Longeveron Inc. has revised its employment agreement with CEO Stephen Willard, adjusting salary deferral, bonus structure, severance, and equity vesting terms.

Longeveron Inc. announced special equity awards for its Executive Chairman, comprising restricted stock units and stock options, to recognize his contributions to a recent financing transaction and his continued service.

Longeveron Inc. announced that Chief Financial Officer Lisa Locklear will resign effective July 10, 2026, to pursue board opportunities, with Controller Marie Washburn expected to succeed her.

Longeveron announced that the FDA no longer considers the ELPIS II trial pivotal after determining the current primary endpoint is insufficient for efficacy.

Longeveron Inc. has repaid executive officers the difference in salary from a temporary reduction and granted restricted stock units following a recent financing transaction.

Longeveron Inc. reported increased net losses and a significant cash burn, raising substantial doubt about its ability to continue as a going concern, while also facing a Nasdaq delisting notice.

Longeveron Inc. reported a widened net loss in Q2 2025, driven by increased R&D expenses for its clinical programs, while securing new funding to extend its cash runway into early 2026.

Longeveron Inc. reports a net loss of $5.0 million for Q1 2025 and expresses concerns about its cash runway, anticipating the need for additional funding by late Q3 2025.

Longeveron Inc. reports a net loss of $4.4 million for the third quarter of 2024, alongside increased revenue driven by clinical trials and manufacturing services.

Longeveron Inc. reports a reduced net loss and increased revenue for the second quarter of 2024, driven by clinical trial and contract manufacturing revenue, while also securing significant funding through warrant exercises and a direct offering.

Longeveron Inc. reported a net loss of $4.1 million for the first quarter of 2024, while highlighting progress in clinical trials and strategic initiatives.

Longeveron Inc. reported a widened net loss for fiscal year 2025 and substantial doubt about its ability to continue as a going concern, despite advancing its lead product candidate, laromestrocel, in multiple clinical programs.

Longeveron's 10-K filing reveals a strategic focus on Hypoplastic Left Heart Syndrome (HLHS) and Alzheimer's disease (AD) programs, alongside financial updates and risk assessments.

Longeveron Inc. has filed an amendment to its annual report to correct errors in the description of its intellectual property, while also providing updates on its clinical development programs.

Longeveron Inc.'s annual 10-K filing details the company's clinical development pipeline, manufacturing capabilities, and financial position for the year ended December 31, 2023.

Longeveron Inc. reports a significant stock transaction by Chief Scientific Officer Joshua Hare, involving restricted stock units and stock options.

Longeveron Inc. CEO Stephen H. Willard reported a disposition of 18,046 shares of Class A Common Stock to cover tax obligations related to vested restricted stock units.

Longeveron Inc. CFO Lisa Locklear reports a transaction involving the withholding of shares for tax obligations and holds a significant number of restricted stock units.

Longeveron Inc. Chief Medical Officer Nataliya Agafonova reported a transaction involving the sale of 22,505 shares of Class A Common Stock to cover tax obligations related to a restricted stock unit award.

Longeveron Inc. CTO Devin Blass reported a transaction involving the sale of company stock to cover tax obligations related to vested restricted stock units.

Longeveron Inc. reports that General Counsel Paul T. Lehr sold 13,143 shares of Class A Common Stock to cover tax obligations related to RSU vesting.

Longeveron Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for July 1, 2026, to address key corporate actions including a significant increase in authorized shares and a reverse stock split.

Longeveron Inc. announces its annual stockholder meeting to be held virtually on June 13, 2025, to vote on director election, an amendment to the incentive award plan, and ratification of the accounting firm.

Longeveron Inc. is holding its 2025 Annual Meeting of Stockholders on June 13, 2025, to elect a director, approve an amendment to the 2021 Incentive Award Plan, and ratify the appointment of CBIZ CPAs P.C. as the independent auditor.

Longeveron Inc. announces its annual shareholder meeting to be held virtually on July 2, 2024, featuring proposals for director elections, an amendment to the incentive award plan, and ratification of the company's accounting firm.

Longeveron Inc. is set to hold its 2024 Annual Meeting of Stockholders virtually on July 2, 2024, to vote on the election of directors, an amendment to the 2021 Incentive Award Plan, and the ratification of the appointment of Marcum LLP as the independent registered public accounting firm.

Longeveron Inc. has filed a registration statement for the resale of up to 30,865,385 shares of its Class A common stock by certain selling stockholders.

Longeveron Inc. filed an S-1/A registration statement to offer up to 3.85 million Class A common shares and 9.62 million Class A common warrants, aiming to raise approximately $5.2 million to fund its clinical development programs amidst a 'going concern' warning.

Longeveron Inc. files an S-1 registration statement to raise up to $5.2 million through a public offering of common stock and warrants to fund ongoing clinical trials for its lead product, laromestrocel.

Longeveron has filed a registration statement for the resale of up to 2,565,392 shares of Class A common stock by selling stockholders, primarily related to recent warrant exercises and offerings.

Longeveron is registering the resale of up to 3,563,764 shares of its Class A common stock by selling stockholders after a recent warrant inducement transaction.

Longeveron has filed an amendment to its Form S-1 registration statement to register the resale of up to 4,967,470 shares of Class A common stock by selling stockholders.

Janus Henderson Group plc has reported beneficial ownership of 5.9% of Longeveron Inc.'s Class A Common Stock as of March 31, 2026.

Lincoln Alternative Strategies LLC has reported a 0% beneficial ownership in Longeveron Inc. common stock, indicating a full divestment or reduction below reporting thresholds.

Lincoln Alternative Strategies LLC has disclosed a passive 6.09% beneficial ownership stake in Longeveron Inc.'s Class A Common Stock.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, disclosed a 9.99% beneficial ownership stake in Longeveron Inc.'s Class A Common Stock.